ImmuPharma (LON:IMM) Shares Up 19.7% - What's Next?

Key Points

• ImmuPharma's shares surged by 19.7% in mid-day trading, reaching as high as GBX 13.50 ($0.18) during the session.
• The company reported a negative earnings per share of GBX (0.38) for the last quarter and is projected to have an EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics, with its lead program focused on treating Lupus and potentially other autoimmune diseases.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 19.7% during mid-day trading on Tuesday . The company traded as high as GBX 13.50 ($0.18) and last traded at GBX 13.23 ($0.18). 14,293,236 shares traded hands during mid-day trading, an increase of 68% from the average session volume of 8,532,263 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Stock Up 9.5%

The business's 50 day moving average is GBX 4.46 and its two-hundred day moving average is GBX 3.33. The firm has a market capitalization of £60.47 million, a P/E ratio of -1,359.55 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.